5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine: Atomic Evidence, Mechanism, and Use

Executive Summary: 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine (SKU: B3465) is a selective small molecule α2-adrenergic receptor (α2-AR) agonist with a molecular weight of 292.13 g/mol and a chemical formula of C11H10BrN5 (source: product_spec). It is highly insoluble in water and ethanol but dissolves efficiently in DMSO at concentrations ≥25.7 mg/mL with ultrasonic assistance (source: product_spec). This compound is validated at ≥98% purity by HPLC and NMR and is primarily used to study α2-AR signaling and immune modulation in translational oncology settings, notably for post-surgical osteosarcoma recurrence (source: Pei et al. 2025). APExBIO supplies this reagent for research use only, with recommended storage at –20°C and prompt use after solution preparation for stability (source: product_spec).

Biological Rationale

α2-adrenergic receptors (α2-ARs) are G protein-coupled receptors that modulate neurotransmitter release, vascular tone, and immune cell signaling. Recent translational studies highlight their role in immune rejection modulation, particularly in the context of post-surgery osteosarcoma recurrence, where tumor immune escape and resistance to checkpoint blockade are persistent challenges (source: Pei et al. 2025). Selective α2-AR agonists such as 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine empower researchers to dissect the immune regulatory mechanisms that underpin T cell activation and tumor microenvironment (TME) modulation (source: internal_article).

Mechanism of Action of 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine

This compound acts as a selective agonist at α2-adrenergic receptors, triggering downstream inhibitory G protein signaling (Gi/o) upon receptor binding. This signaling cascade leads to reduced cyclic AMP production and modulation of immune cell activity. In post-surgery osteosarcoma models, activation of α2-ARs by this agonist results in enhanced CD8+ T cell activation and potentiation of T cell receptor (TCR) signaling, culminating in reduced tumor recurrence in immunocompetent mouse models (source: Pei et al. 2025). Proteomic and bioinformatics analyses further implicate molecules such as ITGAL, MSN, and TOLLIP as core mediators of this immune modulation (source: Pei et al. 2025).

Evidence & Benchmarks

• 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine exhibits ≥98% purity as confirmed by HPLC and NMR, supporting consistent experimental results (source: product_spec).
• This compound is insoluble in water and ethanol but dissolves in DMSO at ≥25.7 mg/mL when ultrasonically assisted, facilitating high-concentration stock solution preparation (source: product_spec).
• In vitro, treatment of osteosarcoma cell lines with the agonist does not significantly impact viability, migration, or invasion, indicating minimal direct cytotoxicity (source: Pei et al. 2025).
• In vivo, α2-AR agonist-loaded hydrogels result in a significant reduction of post-surgical osteosarcoma recurrence in immunocompetent BALB/c mice (source: Pei et al. 2025).
• Proteomic analysis of treated tumors reveals activation of CD8+ T cell and TCR pathways, with ITGAL serving as a key regulatory node (source: Pei et al. 2025).
• The product is shipped on blue ice and recommended for use immediately after solution preparation to maintain stability (source: product_spec).

This article extends the practical guidance found in Applied Strategies Using 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine by providing new benchmarks from recent translational studies and clarifies the immune-specific mechanistic boundaries not covered in this mechanistic synthesis or the robust workflow focus in existing internal analyses.

Applications, Limits & Misconceptions

5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine is primarily validated for use in preclinical research to study α2-adrenergic receptor signaling and immune rejection modulation within oncology models—especially for interrogating post-surgical osteosarcoma recurrence and T cell activation phenomena (source: Pei et al. 2025). Its robust DMSO solubility and high purity enable reliable, reproducible experimental workflows (source: product_spec).

Common Pitfalls or Misconceptions

• Not water-soluble: Attempts to dissolve in aqueous buffers result in precipitation and loss of experimental control (source: product_spec).
• Not cytotoxic in vitro: The molecule does not induce direct cell death in OS cell lines; anti-tumor effects are immune-mediated (source: Pei et al. 2025).
• Not suitable for diagnostic or human therapeutic use: The compound is strictly intended for research applications (source: product_spec).
• Stability is time-sensitive post-dissolution: Prolonged storage after reconstitution leads to degradation (source: product_spec).
• Immune effects may be species/strain-specific: Effects observed in BALB/c mice may not universally translate to other models (source: workflow_recommendation).

Workflow Integration & Parameters

Protocol Parameters

• solvent preference | DMSO (≥25.7 mg/mL with ultrasonic assistance) | all in vitro/in vivo applications | Ensures complete dissolution and homogeneous delivery | product_spec
• purity verification | ≥98% by HPLC/NMR | all research applications | Minimizes confounding variables in signaling assays | product_spec
• storage temperature | –20°C | pre-use reagent storage | Preserves molecular integrity | product_spec
• application window | Use immediately post-reconstitution | all workflows | Limits degradation and preserves activity | product_spec
• in vivo delivery | Thermo-sensitive hydrogel (PLGA-PEG-PLGA) | mouse xenograft models | Sustained local release at tumor site | Pei et al. 2025
• in vitro exposure | 1–100 μM (typical) | OS cell signaling studies | Range covers reported effective concentrations | workflow_recommendation

Conclusion & Outlook

5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine enables precise dissection of α2-adrenergic receptor signaling and immune modulation in translational oncology research. Its performance in post-surgery osteosarcoma recurrence models supports its role in advancing immune rejection modulation strategies. Further research is warranted to define the boundaries of translational relevance and optimize delivery systems. For up-to-date protocols, consult the APExBIO product page.